Events Archive 2021 2021 - 16 December 2021 – Destiny Pharma presents at the 3rd Annual Bio Cross-Border Investment & Partnership event - Biotech Showcase 2022 – 10-12 January 2022 - 3rd Annual Bio Cross-Border Investment & Partnership Summit – 16 December 2021 - Microbiome Connect: Gut Therapeutics Europe – 7-9 December 2021 - 26 November 2021 – SAB Member Prof. Gerding interviewed by Equity Development - 24 November 2021 – Destiny Pharma highlighted in WH Ireland analyst note - German Equity Forum – 22 – 24 November 2021 - Emerging Antimicrobials and Diagnostics in AMR 2021 (EADA 2021) – 18 November 2021 - 04 November 2021 – SAB Member Prof. Gerding is Keynote at C.diff Conference - Jefferies London Healthcare Conference – 16 – 18 November 2021 - C. diff International Conference & Health Expo – 4 – 5 November 2021 - C. diff International Conference & Health Expo – 4 – 5 November 2021 - 18 October 2021 – Major US hospital-based clinical trial highlights benefit of nasal decolonization to reduce ICU infections caused by Staphylococcus aureus - 11 October 2021 – IDSA press release: Drug-resistant Infections Led to $1.9 Billion in Health Care Costs, More Than 10,000 Deaths Among Older Adults in One Year - 27 September 2021 – Expansion of clinical pipeline - 09 September 2021 – Interim results for the 6 months ended 30 June 2021 - 26 August 2021 – Notice of Interim Results and Investor Presentation - BIO-Europe Digital – 25 – 28 October 2021 - ID Week – 29 September – 3 October 2021 - Proactive One2One Virtual Forum – 16 September 2021 - 02 August 2021 – Secondary endpoint analysis from Phase 2b trial - 09 July 2021 – XF-73 Phase 2b data to be presented at ECCMID - 5th AMR Conference Summer Edition / AMR Briefing Sessions – 24 – 26 August 2021 - 06 July 2021 – NTCD-M3 RD Agreement with US Dept Veterans Affairs - 02 July 2021 – Scientific Advisor, Professor Dale Gerding, to chair C. diff. Foundation Symposium - ECCMID 2021 – 9 – 12 July 2021 - Shares & AJ Bell Webinar – 6 July 2021 - 29 June 2021 – Destiny Pharma to present at Shares & AJ Bell Webinar – 6th July 2021 - 10 June 2021 – XF-73 data abstract to be presented at 2021 ECCMID - 07 June 2021 – Destiny Pharma welcomes G7’s Communique on Antimicrobial Resistance - 03 June 2021 – Result of Annual General Meeting - 02 June 2021 – Positive update on microbiome therapeutic NTCD-M3 - 25 May 2021 – Further information re AGM - Microbiome Movement Drug Development – 29 June – 1 July 2021 - BIO Digital – 10-11 June and 14-18 June 2021 - 19 May 2021 – Notice to Register for 2021 AGM - 06 May 2021 – Destiny Pharma Conference Attendance for May 2021 - 04 May 2021 – Equity Development Research Note ‘Destiny Pharma: M3, another gem in the portfolio’ - 04 May 2021 – Posting of Annual Report and Notice of AGM - Bio€quity Europe conference, 17 – 19 May 2021 - Proactive One2One Virtual Forum, 6 May 2021 - 15 Apr 2021 – Investor Presentation – 22 April 2021 at 1400 BST - Pharmabiotics Conference, 28 – 29 April 2021 - 2021 Digital BioInfect conference, 21 – 22 April 2021 - 14 Apr 2021 – Results webcast details - 14 Apr 2021 – Audited results for the year ended 31 December 2020 and positive Phase 2b data announced post year-end - 5th Future Healthcare VB100 Conference, 16 – 18 April 2021 in Suzhou, Jiangsu Province China - 29 Mar 2021 – Destiny Pharma to Join Equity Development Webinar - 29 Mar 2021 – Destiny Pharma Phase 2b results – Analyst and Investor webcast and conference call details – Monday 29th March at 1100 BST - 29 Mar 2021 – Destiny Pharma Reports Positive Phase 2b Results for XF-73 Nasal Gel - 16 Mar 2021 – Notice of Full Year Results and Clinical Trial Update - 15 Mar 2021 – Destiny Pharma Announces Agreement with NIAID - 10 Mar 2021 – Destiny Pharma CSO Joins UKRI COVID-19 Taskforce - BIO-Europe Spring, 22 – 25 March 2021 - 14th Annual European Life Sciences CEO Forum, 10 – 11 March 2021 - H C Wainwright Global Life Sciences Conference on 9 – 10 March 2021 - Shares Investor evening webinar – 3rd February 2021 - 03 Feb 2021 – Destiny Pharma announces Brazilian Patent granted for XF-73 nasal gel - 02 Feb 2021 – Destiny Pharma to join panel discussion at the 7th Annual LSX World Congress 2021 - 02 Feb 2021 – Destiny Pharma appoints Professor Mark Wilcox to Scientific Advisory Board - 27 Jan 2021 – Destiny Pharma welcomes Matt Hancock’s statement saying G7 will focus on AMR - 21 Jan 2021 – Destiny Pharma Investor Presentation - LSX World Congress, 1 – 5 February 2021 - 06 Jan 2021 – Destiny Pharma appoints Stephanie Bewick as Chief Business Officer - 05 Jan 2021 – Phase 2b trial of XF-73 completes recruitment Archive 2021 2020 2019
